1. Kieff E, Rickinson A (2006) Epstein-Barr Virus and Its Replication. In: Knipe D, Howley P, editors. Fields Virology. Fifth Edition ed. Philadelphia, PA: Lippincott Williams & Wilkins. pp. 2626.
2. RoweM, RoweDT, GregoryCD, YoungLS, FarrellPJ, et al. (1987) Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 6: 2743–2751.
3. WoisetschlaegerM, YandavaCN, FurmanskiLA, StromingerJL, SpeckSH (1990) Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. Proc Natl Acad Sci U S A 87: 1725–1729.
4. SampleJ, HummelM, BraunD, BirkenbachM, KieffE (1986) Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. Proc Natl Acad Sci U S A 83: 5096–5100.
5. BodescotM, PerricaudetM, FarrellPJ (1987) A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus. J Virol 61: 3424–3430.
6. SchaeferBC, StromingerJL, SpeckSH (1995) Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc Natl Acad Sci U S A 92: 10565–10569.
7. NonkweloC, SkinnerJ, BellA, RickinsonA, SampleJ (1996) Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J Virol 70: 623–627.
8. MagrathIT (1991) African Burkitt's lymphoma. History, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol 13: 222–246.
9. RoweM, KellyGL, BellAI, RickinsonAB (2009) Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol 19: 377–388.
10. KellyG, BellA, RickinsonA (2002) Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med 8: 1098–1104.
11. LeaoM, AndertonE, WadeM, MeekingsK, AlldayMJ (2007) Epstein-Barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells. J Virol 81: 248–260.
12. KellyGL, LongHM, StylianouJ, ThomasWA, LeeseA, et al. (2009) An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog 5: e1000341.
13. AustinPJ, FlemingtonE, YandavaCN, StromingerJL, SpeckSH (1988) Complex transcription of the Epstein-Barr virus BamHI fragment H rightward open reading frame 1 (BHRF1) in latently and lytically infected B lymphocytes. Proc Natl Acad Sci U S A 85: 3678–3682.
14. PearsonGR, LukaJ, PettiL, SampleJ, BirkenbachM, et al. (1987) Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology 160: 151–161.
15. ZindyF, EischenCM, RandleDH, KamijoT, ClevelandJL, et al. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424–2433.
16. KamijoT, WeberJD, ZambettiG, ZindyF, RousselMF, et al. (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 95: 8292–8297.
17. PomerantzJ, Schreiber-AgusN, LiegeoisNJ, SilvermanA, AllandL, et al. (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713–723.
18. StottFJ, BatesS, JamesMC, McConnellBB, StarborgM, et al. (1998) The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17: 5001–5014.
19. ZhangY, XiongY, YarbroughWG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725–734.
20. Sample JT, Ruf IK (2006) Burkitt Lymphoma In: Tselis A, Johnson HB, editor. Epstein-Barr Virus. New York, NY: Informa Healthcare. pp. 187–222.
21. EischenCM, WeberJD, RousselMF, SherrCJ, ClevelandJL (1999) Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13: 2658–2669.
22. AndertonE, YeeJ, SmithP, CrookT, WhiteRE, et al. (2008) Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 27: 421–433.
23. KellyGL, MilnerAE, BaldwinGS, BellAI, RickinsonAB (2006) Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci U S A 103: 14935–14940.
24. BaerR, BankierAT, BigginMD, DeiningerPL, FarrellPJ, et al. (1984) DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310: 207–211.
25. PettiL, SampleJ, WangF, KieffE (1988) A fifth Epstein-Barr virus nuclear protein (EBNA3C) is expressed in latently infected growth-transformed lymphocytes. J Virol 62: 1330–1338.
26. RickstenA, KallinB, AlexanderH, DillnerJ, FahraeusR, et al. (1988) BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. Proc Natl Acad Sci U S A 85: 995–999.
27. TomkinsonB, KieffE (1992) Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol 66: 2893–2903.
28. TomkinsonB, RobertsonE, KieffE (1993) Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 67: 2014–2025.
29. MaruoS, WuY, IshikawaS, KandaT, IwakiriD, et al. (2006) Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells. Proc Natl Acad Sci U S A 103: 19500–19505.
30. MaruoS, JohannsenE, IllanesD, CooperA, KieffE (2003) Epstein-Barr Virus nuclear protein EBNA3A is critical for maintaining lymphoblastoid cell line growth. J Virol 77: 10437–10447.
31. Le RouxA, KerdilesB, WallsD, DedieuJF, PerricaudetM (1994) The Epstein-Barr virus determined nuclear antigens EBNA-3A, -3B, and -3C repress EBNA-2-mediated transactivation of the viral terminal protein 1 gene promoter. Virology 205: 596–602.
32. JohannsenE, MillerCL, GrossmanSR, KieffE (1996) EBNA-2 and EBNA-3C extensively and mutually exclusively associate with RBPJkappa in Epstein-Barr virus-transformed B lymphocytes. J Virol 70: 4179–4183.
33. ZhaoB, MarshallDR, SampleCE (1996) A conserved domain of the Epstein-Barr virus nuclear antigens 3A and 3C binds to a discrete domain of Jkappa. J Virol 70: 4228–4236.
34. Jimenez-RamirezC, BrooksAJ, ForshellLP, YakimchukK, ZhaoB, et al. (2006) Epstein-Barr virus EBNA-3C is targeted to and regulates expression from the bidirectional LMP-1/2B promoter. J Virol 80: 11200–11208.
35. TouitouR, HickabottomM, ParkerG, CrookT, AlldayMJ (2001) Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C. J Virol 75: 7749–7755.
36. HickabottomM, ParkerGA, FreemontP, CrookT, AlldayMJ (2002) Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP). J Biol Chem 277: 47197–47204.
37. ZhaoB, SampleCE (2000) Epstein-Barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/Spi-B binding site. J Virol 74: 5151–5160.
38. KrauerKG, BurgessA, BuckM, FlanaganJ, SculleyTB, et al. (2004) The EBNA-3 gene family proteins disrupt the G2/M checkpoint. Oncogene 23: 1342–1353.
39. HertleML, PoppC, PetermannS, MaierS, KremmerE, et al. (2009) Differential gene expression patterns of EBV infected EBNA-3A positive and negative human B lymphocytes. PLoS Pathog 5: e1000506.
40. ClybouwC, McHichiB, MouhamadS, AuffredouMT, BourgeadeMF, et al. (2005) EBV infection of human B lymphocytes leads to down-regulation of Bim expression: relationship to resistance to apoptosis. J Immunol 175: 2968–2973.
41. MaruoS, ZhaoB, JohannsenE, KieffE, ZouJ, et al. (2011) Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A 108: 1919–1924.
42. SkalskaL, WhiteRE, FranzM, RuhmannM, AlldayMJ (2010) Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog 6: e1000951.
43. ZhaoB, MarJC, MaruoS, LeeS, GewurzBE, et al. (2011) Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines. Proc Natl Acad Sci U S A 108: 337–342.
44. SkalskaL, WhiteRE, ParkerGA, SinclairAJ, PaschosK, et al. (2013) Induction of p16(INK4a) Is the Major Barrier to Proliferation when Epstein-Barr Virus (EBV) Transforms Primary B Cells into Lymphoblastoid Cell Lines. PLoS Pathog 9: e1003187.
45. KaiserC, LauxG, EickD, JochnerN, BornkammGW, et al. (1999) The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol 73: 4481–4484.
46. CaldwellRG, BrownRC, LongneckerR (2000) Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol 74: 1101–1113.
47. CaldwellRG, WilsonJB, AndersonSJ, LongneckerR (1998) Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9: 405–411.
48. KnutsonJC (1990) The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization. J Virol 64: 2530–2536.
49. PengM, LundgrenE (1992) Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 7: 1775–1782.
50. OhtaniN, BrennanP, GaubatzS, SanijE, HertzogP, et al. (2003) Epstein-Barr virus LMP1 blocks p16INK4a-RB pathway by promoting nuclear export of E2F4/5. J Cell Biol 162: 173–183.
51. RoweM, Peng-PilonM, HuenDS, HardyR, Croom-CarterD, et al. (1994) Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers. J Virol 68: 5602–5612.
52. WatanabeA, MaruoS, ItoT, ItoM, KatsumuraKR, et al. (2010) Epstein-Barr virus-encoded Bcl-2 homologue functions as a survival factor in Wp-restricted Burkitt lymphoma cell line P3HR-1. J Virol 84: 2893–2901.
53. RufIK, RhynePW, YangH, BorzaCM, Hutt-FletcherLM, et al. (1999) Epstein-Barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol Cell Biol 19: 1651–1660.
54. ShimizuN, Tanabe-TochikuraA, KuroiwaY, TakadaK (1994) Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J Virol 68: 6069–6073.
55. RaoL, PerezD, WhiteE (1996) Lamin proteolysis facilitates nuclear events during apoptosis. J Cell Biol 135: 1441–1455.
56. OberhammerFA, HocheggerK, FroschlG, TiefenbacherR, PavelkaM (1994) Chromatin condensation during apoptosis is accompanied by degradation of lamin A+B, without enhanced activation of cdc2 kinase. J Cell Biol 126: 827–837.
57. LazebnikYA, KaufmannSH, DesnoyersS, PoirierGG, EarnshawWC (1994) Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346–347.
58. BuendiaB, Santa-MariaA, CourvalinJC (1999) Caspase-dependent proteolysis of integral and peripheral proteins of nuclear membranes and nuclear pore complex proteins during apoptosis. J Cell Sci 112 (Pt 11) 1743–1753.
59. Dalla-FaveraR, BregniM, EriksonJ, PattersonD, GalloRC, et al. (1982) Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 79: 7824–7827.
60. TaubR, KirschI, MortonC, LenoirG, SwanD, et al. (1982) Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A 79: 7837–7841.
61. AskewDS, AshmunRA, SimmonsBC, ClevelandJL (1991) Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6: 1915–1922.
62. ChencheriSC, TursiellaML, SampleCE (2014) Epstein-Barr virus EBNA-3C contributes to apoptotic resistance but not proliferation of Wp-R BL cells. In Press
63. BarakY, JuvenT, HaffnerR, OrenM (1993) mdm2 expression is induced by wild type p53 activity. EMBO J 12: 461–468.
64. NakanoK, VousdenKH (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7: 683–694.
65. HindsPW, FinlayCA, QuartinRS, BakerSJ, FearonER, et al. (1990) Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the “hot spot” mutant phenotypes. Cell Growth Differ 1: 571–580.
66. PokrovskajaK, Ehlin-HenrikssonB, BartkovaJ, BartekJ, ScuderiR, et al. (1996) Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines. Cell Growth Differ 7: 1723–1732.
67. SherrCJ, RobertsJM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501–1512.
68. XiongY, HannonGJ, ZhangH, CassoD, KobayashiR, et al. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366: 701–704.
69. HarperJW, AdamiGR, WeiN, KeyomarsiK, ElledgeSJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805–816.
70. HarperJW, ElledgeSJ, KeyomarsiK, DynlachtB, TsaiLH, et al. (1995) Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6: 387–400.
71. GuY, TurckCW, MorganDO (1993) Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366: 707–710.
72. el-DeiryWS, TokinoT, VelculescuVE, LevyDB, ParsonsR, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–825.
73. DengC, ZhangP, HarperJW, ElledgeSJ, LederP (1995) Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675–684.
74. CayrolC, FlemingtonEK (1996) The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. EMBO J 15: 2748–2759.
75. CountrymanJ, JensonH, SeiblR, WolfH, MillerG (1987) Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol 61: 3672–3679.
76. RooneyCM, RoweDT, RagotT, FarrellPJ (1989) The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J Virol 63: 3109–3116.
77. JepsenJS, PfundhellerHM, LykkesfeldtAE (2004) Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA). Oligonucleotides 14: 147–156.
78. VereideDT, SugdenB (2011) Lymphomas differ in their dependence on Epstein-Barr virus. Blood 117: 1977–1985.
79. MagrathI (1990) The pathogenesis of Burkitt's lymphoma. Adv Cancer Res 55: 133–270.
80. PaschosK, ParkerGA, WatanatanasupE, WhiteRE, AlldayMJ (2012) BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Res 40: 7233–7246.
81. PaschosK, SmithP, AndertonE, MiddeldorpJM, WhiteRE, et al. (2009) Epstein-Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 5: e1000492.
82. HappoL, CraggMS, PhipsonB, HagaJM, JansenES, et al. (2010) Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. Blood 116: 5256–5267.
83. KnightJS, SharmaN, RobertsonES (2005) Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci U S A 102: 18562–18566.
84. KlangbyU, OkanI, MagnussonKP, WendlandM, LindP, et al. (1998) p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood 91: 1680–1687.
85. CannellEJ, FarrellPJ, SinclairAJ (1996) Epstein-Barr virus exploits the normal cell pathway to regulate Rb activity during the immortalisation of primary B-cells. Oncogene 13: 1413–1421.
86. GalaktionovK, ChenX, BeachD (1996) Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382: 511–517.
87. SinclairAJ, PalmeroI, PetersG, FarrellPJ (1994) EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J 13: 3321–3328.
88. BroudeEV, SwiftME, VivoC, ChangBD, DavisBM, et al. (2007) p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation. Oncogene 26: 6954–6958.
89. SdekP, YingH, ZhengH, MargulisA, TangX, et al. (2004) The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth. J Biol Chem 279: 53317–53322.
90. SdekP, YingH, ChangDL, QiuW, ZhengH, et al. (2005) MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell 20: 699–708.
91. ChangBD, WatanabeK, BroudeEV, FangJ, PooleJC, et al. (2000) Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc Natl Acad Sci U S A 97: 4291–4296.
92. JanickeRU, WalkerPA, LinXY, PorterAG (1996) Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J 15: 6969–6978.
93. ZhangH, HannonGJ, BeachD (1994) p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 8: 1750–1758.
94. LaBaerJ, GarrettMD, StevensonLF, SlingerlandJM, SandhuC, et al. (1997) New functional activities for the p21 family of CDK inhibitors. Genes Dev 11: 847–862.
95. ChengM, OlivierP, DiehlJA, FeroM, RousselMF, et al. (1999) The p21(Cip1) and p27(Kip1) CDK ‘inhibitors’ are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18: 1571–1583.
96. HammerschmidtW, SugdenB (1989) Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340: 393–397.
97. CohenJI, WangF, KieffE (1991) Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol 65: 2545–2554.
98. CohenJI, WangF, MannickJ, KieffE (1989) Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A 86: 9558–9562.
99. AlldayMJ, SinclairA, ParkerG, CrawfordDH, FarrellPJ (1995) Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J 14: 1382–1391.
100. O'NionsJ, AlldayMJ (2003) Epstein-Barr virus can inhibit genotoxin-induced G1 arrest downstream of p53 by preventing the inactivation of CDK2. Oncogene 22: 7181–7191.
101. SahaA, MurakamiM, KumarP, BajajB, SimsK, et al. (2009) Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol 83: 4652–4669.
102. SuiG, SoohooC, Affar elB, GayF, ShiY, et al. (2002) A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci U S A 99: 5515–5520.
103. GorskaA, SwiatkowskaA, DutkiewiczM, CiesiolkaJ (2013) Modulation of p53 expression using antisense oligonucleotides complementary to the 5′-terminal region of p53 mRNA in vitro and in the living cells. PLoS One 8: e78863.
104. LaemmliUK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685.